1[1]Collins R,Armitage J,Parish S,et al.Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions[J].Lancet,2004,363:757-767.
2[2]Amarenco P,Bogousslavsky J,Callahan A 3rd,for Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators.High-dose atorvastatin after stroke or transient ischemic attack[J].N Engl J Med,2006,355:549-559.
3[3]Yildiz A,Cakar MA,Baskurt M,et al.The effects of atorvastatin therapy on endothelial function in patients with coronary artery disease[J].Cardiovasc Ultrasound,2007,5:51.
4[4]Coretti MC,Anderson TJ,Benjamin EJ,et al.Guidelines for the ultrasound assessment of endothelial-dependent-mediated vasodilation of the brachial artery:a report of the international brachial artery reactivity task force[J].J Am Coll Cardiol,2002,39:257-265.
5[5]Chen PL,Wang PY,Sheu WH,et al.Changes of brachial flow-mediated vasodilation in different ischemic stroke subtypes[J].Neurology,2006,67:1056-1058.
6[6]Hoth KF,Tate DF,Poppas A,et al.Endothelial function and white matter hyperintensities in older adults with cardiovascular disease[J].Stroke,2007,38:308-312.
7[7]Corrado E,Rizzo M,Coppola G,et al.Endothelial dysfunction and carotid lesions are strong predictors of clinical events in patients with early stages of atherosclerosis:a 24-month follow-up study[J].Coron Artery Dis,2008,19:139-144.
8[8]Blann AD,McCollum CN,Lip GY,et al.Relationship between plasma markers of endothelial cell integrity and the Framingham cardiovascular disease riskfactor scores in apparently healthy individuals[J].Blood Coagul Fibrino-lysis,2002,13:513-518.
9[9]Felmeden DC,Blann AD,Spencer CG,et al.A comparison of flow-mediated dilatation and von Willebrand factor as markers of endothelial cell function in health and in hypertension:relationship to cardiovascular risk and effects of treatment:a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial[J].Blood Coagul Fibrinolysis,2003,14:425-431.
10[10]Qizilbash N,Duffy S,Prentice CR,et al.Von Willebrand factor and risk of ischemic stroke[J].Neurology,1997,49:1552-1556.
3Calabro P, Yeh ET. Multitasking of the 3-hydroxy-3- methylglutaryl coenzyme a Atheroscler reductase inhibitor: beyond cardiovascular diseases. Curr Rep, 2004, 6:36-41.
4Poredos P, Jezovnik MK. Testing endothelial function and its clinical relevance [ J ]. J Atheroscler Thromb, 2013,20 (1) :1-8.
5Hamburg NM, Keyes MJ, Larson MG, et al. Cross-sectional relations of digital vascular function to cardiovascular risk factors in the Framingham Heart Study [ J ].Circulation, 2008,117 ( 19 ) : 2467-2474.
6Kuvin JT,Patel AR, Sliney KA,et al. Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude [ J ]. Am Heart J, 2003,146 ( 1 ) : 168-174.
7Schoenenberger AW, Urbanek N, Bergner M, et al. As- sociations of reactive hyperemia index and intravascular ul- trasound-assessed coronary plaque morphology in patients with coronary artery disease [ J ]. Am J Cardiol, 2012, 109 (12) :1711-1716.
8Bonetti PO, Pumper GM, Higano ST, et al. Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia[ J]. J Am Coil Cardio1,2004,44 ( 11 ) :2137-2141.
